



Oncology Value Management

Fighting cancer. Improving care. Lowering costs.

When employees or their family members are diagnosed with cancer, they count on their employer-sponsored health coverage to connect them to life-saving care.

Through your standard pharmacy coverage with Blue Cross Blue Shield of Michigan, your business is offering comprehensive support to your employees and their covered family members by:

- Enhancing their cancer care
- Reducing their treatment costs

The Oncology Value Management program focuses on the entire drug regimen for cancer treatment, including medical and pharmacy benefit reviews for chemotherapy, immunotherapy, and supportive care. The program consists of two components: a medical necessity review and a site of care review for select medical specialty drugs. Fully insured groups will receive both components of the program as a base offering. No additional fees will be applicable.

This program is an integrated solution that combines medical and pharmacy benefit drugs into one review, which reduces administrative burden on providers and streamlines patient care. The program consists of:

- Patients' care guided by evidence-based treatment regimens shown to be effective and safe
- A review of clinical appropriateness to identify optimal cancer treatments and maximize the value of care
- **Site of care transition** for select medications to ensure the most cost-effective location is utilized for administration

It's estimated there will be a little over 2 million new cancer cases in the U.S. in 2024.¹

By 2030, cancer care spending in the US is expected to exceed \$230 billion.²

The costs of cancer treatment are unsustainable for groups and members if left unmanaged.

Oncology Value Management

A holistic approach to advancing the standard of cancer care

OncoHealth® our oncology management administrator, provides clinical decision support and a treatment validation platform to health care providers developing cancer treatment plans for our members.

After a health care provider submits a request for care on our clinical review platform:

- 1. OncoHealth® reviews the request in real time against the latest medical evidence.
- 2. The treatment plan request is approved immediately, when it's consistent with nationally accepted best practices for care based on clinical studies.

Note: When the request is inconsistent with that evidence, a OncoHealth® physician is available for a consultation with the member's health care provider to develop a treatment plan based on proven clinical results.



Oncology expertise

- 12 oncologists serve as the primary reviewers and are also available for peer-to-peer conversations about treatment options
- 11 oncology-trained pharmacists reviewing the latest literature
- 11 oncology-trained nurses evaluating appropriateness of supportive care



Web-based, real-time

- Automated clinical review streamlines the process
- 90% of requests are approved on initial attempt using portal steerage to preferred regimens
- 4% of requests are withdrawn, while another 4% are modified to an approvable regimen following peerto-peer discussions
- · Maximum turn-around time is 3 days



Evidence-based

 Clinical review based on BCBSM medical policies, in conjunction with national guidelines and approved compendia recommendations

Help improve your employees' cancer care

Our Oncology Value Management program can identify optimal cancer treatments and maximize the value of care for your employees and their covered family members. We can improve their patient experience and ensure the care is appropriate, while helping better manage the high costs for both you and your employees.

If you're interested in learning more about the program, contact your Blue Cross sales representative or contracted agent.

OncoHealth® is an independent company supporting Blue Cross Blue Shield of Michigan and Blue Care Network by providing cancer support services.

- 1. Cancer.org. Cancer Facts & Figures 2024.
- 2. Mariotto AB, et al. Medical care costs associated with cancer survivorship in the United States. 2020.